![](https://library.celltelligence.com/wp-content/uploads/2021/03/Gilead-Clinical-Trials.png)
$0
New Tecartus Ph2 Trial (ZUMA-25) for R/R Rare B-cell Malignancies
On Tuesday, September 13, a new Gilead / Kite-sponsored Ph2 trial (ZUMA-25) evaluating Tecartus (autologous CD19 CAR-T) in rare B-cell malignancies was observed on CT.gov. Below, Celltelligence provides details for this trial while discussing how Gilead could leverage Tecartus’s indication expansion strategy to differentiate from its main competitors.